<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
   xmlns:content="http://purl.org/rss/1.0/modules/content/"
   xmlns:dc="http://purl.org/dc/elements/1.1/"
   xmlns:atom="http://www.w3.org/2005/Atom"
   xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
   xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
   xmlns:company="http://purl.org/rss/1.0/modules/company"
>
	<channel>
		<title>Latest News - Market Wire News</title>
		<atom:link href="https://marketwirenews.com/rss/news-releases/?s=mura" rel="self" type="application/rss+xml" />
		<link>https://marketwirenews.com</link>
		<description>Market Wire News RSS News Feed for Mural Oncology plc (NASDAQ: MURA)</description>
		<lastBuildDate>Wed, 16 Sep 2026 21:21:57 -0400</lastBuildDate>
		<language>en-US</language>
		<sy:updatePeriod> hourly </sy:updatePeriod>
		<sy:updateFrequency> 60 </sy:updateFrequency>

		<image>
			<url>https://marketwirenews.com/assets/img/icons/favicon-32x32.png</url>
			<title>Market Wire News</title>
			<link>https://marketwirenews.com</link>
			<width>32</width>
			<height>32</height>
		</image>
		<item>
            <title>Market Wire News Hottest Alerts Newsletter</title>
            <link>https://marketwirenews.com/newsletter/</link>
            <pubDate>Wed, 16 Sep 2026 21:21:57 -0400</pubDate>
            <dc:creator><![CDATA[Market Wire News]]></dc:creator>
            <category><![CDATA[Stock Picks]]></category>
            <category><![CDATA[Stock ALerts]]></category>
            <description><![CDATA[Subscribe to Market Wire News newsletter for instant real-time stock alerts, breaking financial news, trending stocks, and portfolio updates delivered to your email & mobile.]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/newsletter/?v=7262</guid>
          </item>
          <item>
            <title>Market Wire News Trending Stocks</title>
            <link>https://marketwirenews.com/trending-stocks/</link>
            <pubDate>Wed, 16 Sep 2026 21:21:57 -0400</pubDate>
            <dc:creator><![CDATA[Market Wire News]]></dc:creator>
            <category><![CDATA[Stock Picks]]></category>
            <category><![CDATA[Stock ALerts]]></category>
            <description><![CDATA[Track today's hottest trending stocks on NASDAQ, NYSE, OTCMKTS & Canadian markets. See massive % gainers, real-time movers, volumes, and linked breaking news updates.]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/trending-stocks/?v=7262</guid>
          </item>
          <item>
            <title>Market Wire News Investor Awarenewss</title>
            <link>https://marketwirenews.com/advertise/</link>
            <pubDate>Wed, 16 Sep 2026 21:21:57 -0400</pubDate>
            <dc:creator><![CDATA[Market Wire News]]></dc:creator>
            <category><![CDATA[Invesor Awareness]]></category>
            <category><![CDATA[Investor Releatios]]></category>
            <description><![CDATA[Stock Promoter, Investor Relations, Investor Awareness, Market Wire News, investor brand advertisement services, plans and pricing.]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/advertise/?v=7262</guid>
          </item>
		<item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews December 05, 2025 07:45:00 am</title>
            <link>https://marketwirenews.com/stock/mura/news/mural-oncology-announces-effectiveness-of-scheme-of--6684698317399050.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 05 Dec 2025 07:45:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (&#x201C;   Mural   &#x201D;) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the &#x201C;   Scheme   &#x201D;) pursuant...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/mural-oncology-announces-effectiveness-of-scheme-of--6684698317399050.html?s=mura?v=<?php echo 7262;?></guid>
            </item><item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews December 03, 2025 04:30:00 pm</title>
            <link>https://marketwirenews.com/stock/mura/news/mural-oncology-announces-sanction-of-the-scheme-by-t-4666580946331785.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 03 Dec 2025 16:30:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (&#x201C;   Mural   &#x201D;)&#xA0;announces that the High Court of Ireland has today sanctioned the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/mural-oncology-announces-sanction-of-the-scheme-by-t-4666580946331785.html?s=mura?v=<?php echo 7262;?></guid>
            </item><item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews November 26, 2025 09:00:00 am</title>
            <link>https://marketwirenews.com/stock/mura/news/mural-oncology-announces-final-cash-consideration-pa-5910076609872517.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 26 Nov 2025 09:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (&#x201C;   Mural   &#x201D;)&#xA0;announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (Nasdaq: XOMA) (&#x201C;   XOMA Royalty   &#x201D;)...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/mural-oncology-announces-final-cash-consideration-pa-5910076609872517.html?s=mura?v=<?php echo 7262;?></guid>
            </item><item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews October 24, 2025 04:25:31 pm</title>
            <link>https://marketwirenews.com/stock/mura/news/mural-oncology-announces-that-mural-shareholders-app-4931208261691265.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 24 Oct 2025 16:25:31 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION       WALTHAM, Mass. and DUBLIN, Ireland, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/mural-oncology-announces-that-mural-shareholders-app-4931208261691265.html?s=mura?v=<?php echo 7262;?></guid>
            </item><item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews September 23, 2025 07:52:56 pm</title>
            <link>https://marketwirenews.com/stock/mura/news/mural-oncology-announces-commencement-of-mailing-of--7376868807666273.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 23 Sep 2025 19:52:56 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (&#x201C;   Mural   &#x201D;), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the &#x201C;   Irish Take...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/mural-oncology-announces-commencement-of-mailing-of--7376868807666273.html?s=mura?v=<?php echo 7262;?></guid>
            </item><item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews September 23, 2025 01:51:00 pm</title>
            <link>https://marketwirenews.com/stock/mura/news/shareholder-investigation-halper-sadeh-llc-investiga-6085061672420028.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 23 Sep 2025 13:51:00 -0400</pubDate>
            <dc:creator><![CDATA[PR Newswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CBAN, HBI, NWE, MURA on Behalf of Shareholders           PR Newswire             NEW YORK     ,     Sept. 23, 2025     /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential vio...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/shareholder-investigation-halper-sadeh-llc-investiga-6085061672420028.html?s=mura?v=<?php echo 7262;?></guid>
            </item><item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews August 28, 2025 11:23:00 am</title>
            <link>https://marketwirenews.com/stock/mura/news/shareholder-investigation-halper-sadeh-llc-investiga-7564674033524434.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 28 Aug 2025 11:23:00 -0400</pubDate>
            <dc:creator><![CDATA[PR Newswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWE, BKH, MURA, SCPH on Behalf of Shareholders           PR Newswire             NEW YORK     ,     Aug. 28, 2025     /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential viol...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/shareholder-investigation-halper-sadeh-llc-investiga-7564674033524434.html?s=mura?v=<?php echo 7262;?></guid>
            </item><item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews August 04, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/mura/news/mural-oncology-announces-second-quarter-financial-re-7325994291234390.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 04 Aug 2025 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[Mural continues to explore strategic alternatives         Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by year end       WALTHAM, Mass. and DUBLIN, Aug. 04, 2025 (GLOBE NEWSWIRE...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/mural-oncology-announces-second-quarter-financial-re-7325994291234390.html?s=mura?v=<?php echo 7262;?></guid>
            </item><item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews April 15, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/mura/news/mural-oncology-announces-plans-to-explore-strategic--8408129316467763.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 15 Apr 2025 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin         With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/mural-oncology-announces-plans-to-explore-strategic--8408129316467763.html?s=mura?v=<?php echo 7262;?></guid>
            </item><item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews March 25, 2025 06:30:00 am</title>
            <link>https://marketwirenews.com/stock/mura/news/mural-oncology-provides-update-on-phase-3-artistry-7-7579419806381806.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 25 Mar 2025 06:30:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis         Continued demonstration of favorable tolerability profile generally consistent with previously reported data; over 800 patients treated across ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/mural-oncology-provides-update-on-phase-3-artistry-7-7579419806381806.html?s=mura?v=<?php echo 7262;?></guid>
            </item><item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews March 11, 2025 04:01:00 pm</title>
            <link>https://marketwirenews.com/stock/mura/news/mural-oncology-announces-fourth-quarter-and-year-end-6011934663482770.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 11 Mar 2025 16:01:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025         Top-line data readout of potentially registrational phase 2 ARTISTRY-6 (cohort 2) trial in mucosal melanoma expected in Q2 202...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/mural-oncology-announces-fourth-quarter-and-year-end-6011934663482770.html?s=mura?v=<?php echo 7262;?></guid>
            </item><item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews February 18, 2025 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/mura/news/mural-oncology-to-present-at-the-td-cowen-45th-annua-7475314862681835.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 18 Feb 2025 07:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) --   Mural Oncology plc   (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cow...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/mural-oncology-to-present-at-the-td-cowen-45th-annua-7475314862681835.html?s=mura?v=<?php echo 7262;?></guid>
            </item><item>
            <title>$MURA Mural Oncology plc #MWN #BreakingNews January 09, 2025 04:00:00 pm</title>
            <link>https://marketwirenews.com/stock/mura/news/mural-oncology-highlights-pipeline-progress-and-anti-5224435665042327.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 09 Jan 2025 16:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[MURA]]></category>
            <category><![CDATA[Mural Oncology plc]]></category>
            <description><![CDATA[Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma         Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutane...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/mura/news/mural-oncology-highlights-pipeline-progress-and-anti-5224435665042327.html?s=mura?v=<?php echo 7262;?></guid>
            </item>
	</channel>
</rss>